Introduction
Experimental
| Encapsulationefficiency | Zeta potential | Polydispersity index | Size | Formulation |
|---|---|---|---|---|
| 87.5 ± 3.8 | 0.6 ± 0.7 | 0.14 | 115 | Control (F1) |
| 71 ± 4.08 | 6.1 ± 7.1 | 0.11 | 102 | Limonene (F2) |
Authors
Gene therapy is in its development stage as a novel method for cancer treatment. Liposomes look promising as gene delivery vectors; however, investigations have shown that these vesicles are not doing well in some cases. It was decided here to investigate the possibility of augmentation of liposomal gene delivery by chemical penetration enhancers.
Cationic liposome containing antisense oligonucleotide (AsODN) against lung cancer was prepared by ethanol injection method. Liposomal cineole and limonene (as enhancers) were prepared by film hydration method. Isopropyl myristate (IPM) was also investigated as penetration enhancer. Liposomes were evaluated for their size, zeta potential and encapsulation efficiency. Cancer cells (A549) were pretreated with liposomal terpenes prior to treatment with liposomal antisense or scrambled oligonucleotide. Cell viability was evaluated by MTT assay.
Oligonucleotide -containing liposome showed particle size of about115 nm and zeta potential of 0.6 mV. Liposomal cineole significantly (P<0.05) increased specific activity of liposomal antisense but limonene didn’t show such an effect. IPM increased both specific and non-specific cytotoxicity of Oligonucleotide.
These results show that penetration enhancers (such as cineole) may be used for improving liposomal gene delivery and to reduce non-specific toxicity. Concentration and chemical nature of enhancer has prominent effect in their efficacy.
| Encapsulationefficiency | Zeta potential | Polydispersity index | Size | Formulation |
|---|---|---|---|---|
| 87.5 ± 3.8 | 0.6 ± 0.7 | 0.14 | 115 | Control (F1) |
| 71 ± 4.08 | 6.1 ± 7.1 | 0.11 | 102 | Limonene (F2) |
© 2016 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services . This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Saffari M, H. Shirazi F, Oghabian MA, Moghimi HR. Preparation and in-vitro Evaluation of an Antisense-containing Cationic Liposome against Non-small Cell Lung Cancer: a Comparative Preparation Study. Iran J Pharm Res. 2013;12(Suppl):e125606. doi: https://doi.org/10.22037/ijpr.2013.1266
Abedi Gaballu F, Abbaspour-Ravasjani S, Mansoori B, Yekta R, Hamishehkar H, et al. Comparative of in-vitro Evaluation between Erlotinib Loaded Nanostructured Lipid Carriers and Liposomes against A549 Lung Cancer Cell Line. Iran J Pharm Res. 2019;18(3):e126197. doi: https://doi.org/10.22037/ijpr.2019.1100775
Fattahi A, Shahbazi B, Hosseinzadeh L, Mohammadi G. Optimization of Lipofectamine-2000/siRNALipoplexLoaded PLGANanoparticles for Efficient EGFR Gene Silencing: An in Vitro Study. J Rep Pharm Sci. 2018;7(1):e147599. doi:
Moghimipour E, Salami A, Monjezi M. Formulation and Evaluation of Liposomes for Transdermal Delivery of Celecoxib. Jundishapur J Nat Pharm Prod. 2015;10(1):e17653. doi: https://doi.org/10.17795/jjnpp-17653
Saffari M, Moghimi HR, Dass CR. Barriers to Liposomal Gene Delivery: from Application Site to the Target. Iran J Pharm Res. 2016;15(Suppl):e125110. doi: https://doi.org/10.22037/ijpr.2016.1859
More by these authors
Last Update: 1 week ago
Last Update: 1 week ago
Last Update: 1 week ago
Last Update: 2 days ago